Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Rizvi, N. A.; Gettinger, S. N.; Goldman, J. W.; Hellmann, M. D.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J. R.; Shen, Y.; Harbison, C.; Nathan, F.; Ready, N.; Antonia, S. J. |
| Abstract Title: | Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC) |
| Meeting Title: | 16th World Conference on Lung Cancer (WCLC) |
| Keywords: | ipilimumab; immunotherapy; pd-l1; nivolumab |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 10 |
| Issue: | 9 Suppl. 2 |
| Meeting Dates: | 2015 Sep 6-9 |
| Meeting Location: | Denver, CO |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S176 |
| Language: | English |
| ACCESSION: | WOS:000370365100217 |
| PROVIDER: | wos |
| PUBMED: | 26710300 |
| DOI: | 10.1016/S1556-0864(16)30010-7 |
| Notes: | Meeting Abstract: ORAL02.05 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work